Condition
Rabies Human
Total Trials
7
Recruiting
0
Active
0
Completed
5
Success Rate
83.3%-3% vs avg
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
83.3%
-3.2% vs benchmark
Late-Stage Pipeline
57%
4 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results83% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (1)
P 3 (3)
P 4 (1)
Trial Status
Completed5
Enrolling By Invitation1
Terminated1
Trial Success Rate
83.3%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT05382650Terminated
Survey of Human Rabies Immune Globulin Safety in Children
NCT05545371Phase 3Enrolling By InvitationPrimary
Prevention of Rabies With Four Doses of Rabies Vaccine
NCT05549908Phase 3CompletedPrimary
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
NCT06177249Phase 3CompletedPrimary
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
NCT03557008Phase 4CompletedPrimary
Responses to Rabies Vaccine in Adults With or Without Antibiotics
NCT04495569Phase 1Completed
A Bridging Study of the SYN023 on Healthy Adult Subjects
NCT04213950Not ApplicableCompleted
Improving Adherence to Rabies PEP Guideline Recommendations
Showing all 7 trials